The benefit and risk of adding immunotherapy to chemoradiotherapy as the first-line treatment for limited-stage small cell lung cancer: a meta-analysis of randomized controlled trials Authors: Xiang Fu, Yuanya Zhang, Yun Xu, Wenying Chen, Qingjian Hou, Wenxiong Zhang, Wen Zheng Published: 2025 ABSTRACT BackgroundLimited-stage small cell lung cancer (LS-SCLC) remains a highly aggressive malignancy with limited long-term survival despite standard chemoradiotherapy (CRT). Recently, immunotherapy has emerged as a promising adjunct to CRT, but its efficacy and safety in the first-line treatment of LS-SCLC remain uncertain. This meta-analysis of randomized controlled trials (RCTs) aimed to systematically evaluate the clinical benefits and risks of combining immunotherapy with CRT (ICRT) versus CRT alone in patients with LS-SCLC.MethodsRCTs comparing ICRT and CRT as initial therapy for LS-SCLC were retrieved from 6 databases. Data on overall survival (OS), progression-free survival (PFS), responses, and adverse events (AEs) were extracted. Pooled hazard ratios (HRs) or risk ratios (RRs) with 95% confidence intervals (CIs) were calculated using random-effects or fixed-effects models, depending on heterogeneity.ResultsA total of 6 RCTs comprising 1036 patients were included. Compared with CRT alone, ICRT significantly improved OS (HR: 0.80 [0.67, 0.96], P = 0.02) and PFS (HR: 0.78 [0.65, 0.94], P = 0.008). Subgroup analyses of OS and PFS demonstrated that time from end of concurrent CRT to randomization < 14 day, and platinum type - carboplatin were favorable factors for ICRT group. The objective response rate (ORR), and disease control rate (DCR) were similar between the two group. However, the ICRT therapy was associated with more total/ grade 3–5 immune-related AEs (irAEs). The most common irAEs were hypothyroidism (13.64%), and pneumonitis (11.74%) in the ICRT group.ConclusionFirst-line ICRT significantly improves survival outcomes in patients with LS-SCLC compared to CRT alone, albeit with a higher risk of irAEs.PROSPERO registration IDCRD420251076364Supplementary InformationThe online version contains supplementary material available at 10.1186/s12957-025-04150-0. Introduction Small cell lung cancer (SCLC) represents a fast-growing cancer of neuroendocrine origin and makes up roughly 13–15% of total lung malignancies [1]. Among its subtypes, limited-stage SCLC (LS-SCLC) involves a single hemithorax and is amenable to definitive local therapy, thus offering curative potential [2]. For decades, concurrent chemoradiotherapy (CRT) using platinum-based chemotherapy and thoracic radiotherapy has been the standard of care. Despite favorable initial responses, the majority of patients experience relapse, and long-term prognosis remains dismal, with 5-year overall survival (OS) rates reported at 20–30% [3]. The limited progress in improving the prognosis of LS-SCLC has sparked interest in immunotherapy, particularly targeting PD-1 or PD-L1 [4]. In extensive-stage SCLC, trials such as IMpower133 and CASPIAN have shown that adding immunotherapy to chemotherapy improves survival [5]– [6]. These successes have prompted exploration of immunotherapy in the limited-stage setting, where curative treatment is possible. Biological rationale supports this approach: SCLC has high tumor mutational burden and neoantigen expression, enhancing immune visibility [7]. Additionally, radiotherapy may augment immune responses by releasing tumor-associated antigens and upregulating PD-L1 expression, potentially synergizing with immune checkpoint inhibitors (ICIs). These mechanisms provide a theoretical basis for combining CRT and immunotherapy to extend disease control and reduce recurrence [8]. Nevertheless, this therapeutic approach is still investigational in LS-SCLC, and there is no robust scientific evidence to support its routine clinical use at present. While early-phase trials and retrospective studies suggest benefit, randomized controlled trials (RCTs) are few, and their results vary due to differences in trial design, agents used, and treatment timing [9, 10]. Concerns also exist about overlapping toxicities, particularly immune-related adverse events such as pneumonitis and esophagitis, in patients already receiving aggressive CRT. Thus, ICRT should be regarded as an experimental strategy under active clinical investigation rather than a widely accepted standard treatment. To date, no meta-analysis has specifically focused on evaluating chemoradiotherapy plus immunotherapy (ICRT)—defined as either concurrent administration of ICIs with CRT followed by maintenance therapy or sequential immunotherapy after CRT—versus CRT alone in LS-SCLC based solely on RCTs. Existing reviews often combine data from both limited- and extensive-stage disease or include non-randomized studies, limiting their clinical relevance. Within this framework, a detailed meta-analysis of RCTs was performed to assess long-term outcomes and tolerability of ICRT compared with CRT in LS-SCLC patients. By synthesizing the latest high-quality evidence, this study aims to guide clinicians and enhance therapeutic approaches for affected patients. Materials and methods Search strategy The study protocol was prospectively registered in the PROSPERO database (registration ID: CRD420251076364) and is publicly accessible at the following link: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251076364. A structured retrieval strategy was employed, incorporating terms such as “Randomized”, “Limited-stage”, “Lung cancer”, and “Immune checkpoint inhibitors” (Table S1). Eligible publications were sourced through Cochrane Library, Scopus, EMBASE, PubMed, ScienceDirect, and Web of Science, including articles available from inception to September 14, 2025. Selection criteria The inclusion standards were: (1) RCTs published in English; (2) participants confirmed with LS-SCLC; (3) comparisons of first line CRT versus ICRT, including trials in which ICIs were administered either concurrently with CRT or sequentially after CRT completion; (4) documentation of at least one outcome, such as OS, progression-free survival (PFS), response rates, or adverse reactions (AEs). Studies were excluded if they met any of the following: (1) case reports, literature reviews, or meta-analyses; (2) studies that did not contain usable data. Data extraction A predefined extraction form was employed by two independent reviewers to systematically collect study data. Information included study profiles (e.g., lead author, sample size), inclusion/exclusion (I/E) criteria, efficacy outcomes (OS, PFS), response indicators (e.g., objective response rate [ORR], disease control rate [DCR]), and adverse effects (e.g., immune-related AEs [irAEs]). Disagreements were addressed via discussion or resolved by a third evaluator if unresolved. Outcome assessments Subgroup analyses of OS and PFS were categorized by variables such as age, gender, race, ECOG PS, smoking status, disease stage, time from end of concurrent CRT to randomization, receipt of prophylactic cranial irradiation, best response to concurrent CRT, radiotherapy schedule, PD-1/PD-L1 inhibitors type, platinum type, and ICI administration timing (concurrent vs. sequential). AEs were further grouped into treatment-emergent AEs (TEAEs), treatment-related AEs (TRAEs), and irAEs. Tumor response was evaluated according to the RECIST v1.1 [11]. Quality assessment Quality-related data were derived from published papers and, where accessible, from trial registration records. Study bias and design rigor were judged via the Cochrane tool and Jadad score [12, 13]. A score from 4 to 7 indicated high study quality. In addition, the GRADE method was applied to assess evidence certainty, ranked from high to very low [14]. Statistical analysis Data analyses were performed using STATA 17.0 and RevMan 5.4 software. Combined HRs and RRs were calculated to assess time-to-event and binary outcomes. Study heterogeneity was tested with the I² index and Q statistic; substantial variation was suggested by I² >50% or p < 0.10. A random-effects model was used for high heterogeneity, while fixed-effects were adopted when low heterogeneity was observed. Publication bias was explored via funnel plots, and robustness was confirmed through sensitivity analyses. A p-value under 0.05 indicated statistical significance. Results Search results This meta-analysis included 6 RCTs, enrolling a total of 1036 LS-SCLC participants [9, 10, 15–18]. The selection flowchart is displayed in Fig. 1, following PRISMA 2020 standards. As shown in Figure S1 and Table S2, most studies had strong methodologies and low risk of bias. Using the GRADE system, evidence strength ranged from moderate to high (Table S3). Half of the studies were conducted in China [15–17], while the rest involved multinational, multi-center cohorts [9, 10, 18]. Table 1. outlines the basic design and demographic profiles. Four trials (ADRIATIC, GASTO-1052, NCT03540420, and STIMULI) employed sequential immunotherapy, in which immunotherapy was given as maintenance therapy following completion of chemoradiotherapy [9, 10, 17, 18]. Two trials (AdvanTIG-204 and ChiCTR2000032275) used concurrent immunotherapy administered alongside CRT, followed by sequential maintenance immunotherapy [15, 16]. The inclusion/exclusion criteria of the included studies were showed in Table S4. Fig. 1Flow chart Flow chart Table 1Baseline characteristics of the included studiesStudyCountryPhaseGroupsPatientsSex (Male, n [%])Age (Mean, year)Stage, n (%)PCI, n (%)PD-1/PD-L1 typePlatinum typeRadiotherapy, n (%)ICI administration timingFollow up (months)IIIIIIQDBIDADRIATIC [9]Global multicenterPhase IIIICRT264178 (67.4%)6233 (12.5%)231 (87.5%)142 (53.8%)DurvalumabCisplatin/Carboplatin195 (73.9%)69 (26.1%)sICRT37.2CRT266188 (70.7%)6234 (12.8%)232 (87.2%)143 (53.8%)187 (70.3%)79 (29.7%)AdvanTIG-204 [14]ChinaPhase IIICRT42-----0 (0%)TislelizumabCisplatin/Carboplatin42 (100%)0 (0%)cICRT18CRT43-----0 (0%)43 (100%)0 (0%)ChiCTR2000032275 [15]ChinaPhase IIICRT17-----0 (0%)CamrelizumabCisplatin/Carboplatin0 (0%)17 (100%)cICRT10.6CRT17-----0 (0%)0 (0%)17 (100%)GASTO-1052 [16]ChinaPhase IIICRT3125 (80.7%)623 (9.7%)28 (90.3%)25 (80.7%)ToripalimabCisplatin6 (19.4%)25 (80.7%)sICRT25CRT3328 (84.9%)593 (9.1%)30 (90.9%)24 (72.7%)9 (27.3%)24 (72.7%)NCT03540420 [17]Global multicenterPhase IIICRT85-----57 (67.1%)AtezolizumabCisplatin/Carboplatin--sICRT45.1CRT85-----57 (67.1%)--STIMULI [10]Global multicenterPhase IIICRT7850 (64.1%)61.12 (2.6%)9 (11.5%)67 (85.9%)78 (100%)NivolumabCisplatin/Carboplatin48 (61.5%)30 (38.5%)sICRT22.4CRT7542 (56.0%)61.93 (4.0%)7 (9.3%)65 (86.7%)75 (100%)49 (65.3%)26 (34.7%)Abbreviations: BID Bis in die, cICRT Concurrent immune checkpoint inhibitor plus chemoradiotherapy followed by maintenance immune checkpoint inhibitor, CRT Chemoradiotherapy, ICRT Immunotherapy plus chemoradiotherapy, PCI Prophylactic cranial irradiation, PD-1 Programmed death-1 PD-L1 Programmed death-ligand 1, QD Quaque die, sICRT Sequential immune checkpoint inhibitor following chemoradiotherapy Table 1Baseline characteristics of the included studiesStudyCountryPhaseGroupsPatientsSex (Male, n [%])Age (Mean, year)Stage, n (%)PCI, n (%)PD-1/PD-L1 typePlatinum typeRadiotherapy, n (%)ICI administration timingFollow up (months)IIIIIIQDBIDADRIATIC [9]Global multicenterPhase IIIICRT264178 (67.4%)6233 (12.5%)231 (87.5%)142 (53.8%)DurvalumabCisplatin/Carboplatin195 (73.9%)69 (26.1%)sICRT37.2CRT266188 (70.7%)6234 (12.8%)232 (87.2%)143 (53.8%)187 (70.3%)79 (29.7%)AdvanTIG-204 [14]ChinaPhase IIICRT42-----0 (0%)TislelizumabCisplatin/Carboplatin42 (100%)0 (0%)cICRT18CRT43-----0 (0%)43 (100%)0 (0%)ChiCTR2000032275 [15]ChinaPhase IIICRT17-----0 (0%)CamrelizumabCisplatin/Carboplatin0 (0%)17 (100%)cICRT10.6CRT17-----0 (0%)0 (0%)17 (100%)GASTO-1052 [16]ChinaPhase IIICRT3125 (80.7%)623 (9.7%)28 (90.3%)25 (80.7%)ToripalimabCisplatin6 (19.4%)25 (80.7%)sICRT25CRT3328 (84.9%)593 (9.1%)30 (90.9%)24 (72.7%)9 (27.3%)24 (72.7%)NCT03540420 [17]Global multicenterPhase IIICRT85-----57 (67.1%)AtezolizumabCisplatin/Carboplatin--sICRT45.1CRT85-----57 (67.1%)--STIMULI [10]Global multicenterPhase IIICRT7850 (64.1%)61.12 (2.6%)9 (11.5%)67 (85.9%)78 (100%)NivolumabCisplatin/Carboplatin48 (61.5%)30 (38.5%)sICRT22.4CRT7542 (56.0%)61.93 (4.0%)7 (9.3%)65 (86.7%)75 (100%)49 (65.3%)26 (34.7%)Abbreviations: BID Bis in die, cICRT Concurrent immune checkpoint inhibitor plus chemoradiotherapy followed by maintenance immune checkpoint inhibitor, CRT Chemoradiotherapy, ICRT Immunotherapy plus chemoradiotherapy, PCI Prophylactic cranial irradiation, PD-1 Programmed death-1 PD-L1 Programmed death-ligand 1, QD Quaque die, sICRT Sequential immune checkpoint inhibitor following chemoradiotherapy Baseline characteristics of the included studies Abbreviations: BID Bis in die, cICRT Concurrent immune checkpoint inhibitor plus chemoradiotherapy followed by maintenance immune checkpoint inhibitor, CRT Chemoradiotherapy, ICRT Immunotherapy plus chemoradiotherapy, PCI Prophylactic cranial irradiation, PD-1 Programmed death-1 PD-L1 Programmed death-ligand 1, QD Quaque die, sICRT Sequential immune checkpoint inhibitor following chemoradiotherapy Survival ICRT showed a statistically significant improvement in OS (HR: 0.80 [0.67–0.96], P = 0.02) (Fig. 2). Between 12 and 54 months, the OS rate (OSR) consistently favored patients receiving ICRT (Figure S2). The OSR benefit of ICRT became more evident during follow-up from 6 to 54 months (Fig. 3). Fig. 2Forest plot of overall survival and progression-free survival associated with ICRT versus CRT Forest plot of overall survival and progression-free survival associated with ICRT versus CRT Fig. 3Comparisons of OSR associated with ICRT versus CRT. A OSR at 6–60 months; (B) Trend of risk ratios in OSR Comparisons of OSR associated with ICRT versus CRT. A OSR at 6–60 months; (B) Trend of risk ratios in OSR PFS also improved significantly with ICRT (HR: 0.78 [0.65–0.94], P = 0.008) (Fig. 2). From month 12 to 42, patients treated with ICRT maintained PFS rates (PFSR) (Figure S3). The PFSR benefit of ICRT became more evident during follow-up from 6 to 36 months (Fig. 4). Fig. 4Comparisons of PFSR associated with ICRT versus CRT. A PFSR at 6–48 months; (B) Trend of risk ratios in PFSR Comparisons of PFSR associated with ICRT versus CRT. A PFSR at 6–48 months; (B) Trend of risk ratios in PFSR Subgroup analysis We performed predefined subgroup analyses of OS and PFS according to baseline characteristics (details in outcome assessments). OS and PFS were consistently beneficial for ICRT group in patients with stage III disease, current/former smokers, early initiation of ICI after CRT—particularly randomization within < 14 days, carboplatin-based chemotherapy, and patients treated with durvalumab. Additional findings included a PFS benefit among White patients, patients with stable disease after concurrent CRT, and patients receiving sequential ICI administration after CRT (sICRT). Conversely, several clinically important subgroups did not show a statistically significant benefit (all p > 0.05): patients aged < 65 or ≥ 65 years, female patients, those with ECOG 0 or 1 (separately), patients with stage I–II disease, patients receiving once-daily thoracic radiotherapy, and patients treated with nivolumab or atezolizumab in the included trials. Full subgroup data are presented in Table 2. Table 2Subgroup analysis of overall survival and progression-free survivalSubgroupsOverall SurvivalProgression-free survivalPatientsHR (95% CI) P PatientsHR (95% CI) P Total9170.80 [0.67, 0.96]0.0210020.78 [0.65, 0.94]0.008Age < 65 years3850.79 [0.59, 1.06]0.123850.80 [0.61, 1.04]0.10 >65 years2570.76 [0.55, 1.05]0.092570.83 [0.62, 1.13]0.24Sex Female2250.79 [0.52, 1.18]0.252250.72 [0.50, 1.04]0.08 Male4580.77 [0.60, 1.00]0.054580.86 [0.67, 1.09]0.20Race Asia3160.77 [0.58, 1.04]0.094010.82 [0.62, 1.07]0.14 White2670.75 [0.53, 1.06]0.102670.68 [0.49, 0.94]0.02ECOG PS 03121.25 [0.23, 6.81]0.803121.08 [0.35, 3.39]0.89 13670.82 [0.61, 1.10]0.193670.85 [0.65, 1.11]0.22Smoking status Current/former6340.76 [0.61, 0.95]0.024810.78 [0.62, 0.99]0.04 Never---490.62 [0.28, 1.40]0.25Stage I-II670.92 [0.40, 2.11]0.84670.71 [0.35, 1.43]0.34 III4630.71 [0.55, 0.91]0.0084630.77 [0.61, 0.98]0.03Time from end of concurrent CRT to randomization < 14 days640.47 [0.24, 0.92]0.03640.45 [0.24, 0.84]0.01 14–28 days1590.59 [0.38, 0.91]0.021590.89 [0.59, 1.34]0.58 >28 days3070.90 [0.64, 1.27]0.553070.79 [0.58, 1.07]0.13Receipt of prophylactic cranial irradiation Yes4380.82 [0.61, 1.09]0.164380.82 [0.63, 1.06]0.13 No2450.71 [0.51, 0.99]0.043300.80 [0.61, 1.05]0.11Best response to concurrent CRT Complete response850.98 [0.49, 1.97]0.96850.96 [0.52, 1.76]0.90 Partial response5160.80 [0.62, 1.02]0.075160.86 [0.68, 1.08]0.19 Stable disease740.54 [0.25, 1.15]0.11740.50 [0.26, 0.95]0.03Radiotherapy schedule Once daily4790.99 [0.49, 2.02]0.985640.84 [0.68, 1.05]0.12 Twice daily2040.59 [0.38, 0.91]0.022040.69 [0.47, 1.02]0.06PD-1/PD-L1 inhibitors type Nivolumab1530.94 [0.59, 1.50]0.791531.01 [0.65, 1.56]0.96 Toripalimab640.89 [0.54, 1.48]0.65640.47 [0.22, 1.01]0.05 Atezolizumab1700.88 [0.58, 1.33]0.541700.88 [0.60, 1.29]0.51 Durvalumab5300.73 [0.57, 0.93]0.015300.76 [0.61, 0.95]0.02 Tislelizumab---850.80 [0.45, 1.43]0.45Platinum type Cisplatin4150.84 [0.65, 1.08]0.174150.80 [0.62, 1.04]0.10 Carboplatin1790.56 [0.35, 0.89]0.011790.61 [0.41, 0.90]0.01ICI administration timing cICRT---850.80 [0.45, 1.43]0.45 sICRT9170.80 [0.67, 0.96]0.029170.78 [0.65, 0.94]0.01Abbreviations: CRT Chemoradiotherapy, CI Confidence interval, cICRT Concurrent immune checkpoint inhibitor plus chemoradiotherapy followed by maintenance immune checkpoint inhibitor, ECOG PS Eastern Cooperative Oncology Group Performance Status, HR Hazard ratio, ICRT Immunotherapy plus chemoradiotherapy, OS Overall survival, P Probability, PD-1 Programmed death-1, PD-L1 Programmed death-ligand 1, PFS Progression-free survival, sICRT Sequential immune checkpoint inhibitor following chemoradiotherapy Table 2Subgroup analysis of overall survival and progression-free survivalSubgroupsOverall SurvivalProgression-free survivalPatientsHR (95% CI) P PatientsHR (95% CI) P Total9170.80 [0.67, 0.96]0.0210020.78 [0.65, 0.94]0.008Age < 65 years3850.79 [0.59, 1.06]0.123850.80 [0.61, 1.04]0.10 >65 years2570.76 [0.55, 1.05]0.092570.83 [0.62, 1.13]0.24Sex Female2250.79 [0.52, 1.18]0.252250.72 [0.50, 1.04]0.08 Male4580.77 [0.60, 1.00]0.054580.86 [0.67, 1.09]0.20Race Asia3160.77 [0.58, 1.04]0.094010.82 [0.62, 1.07]0.14 White2670.75 [0.53, 1.06]0.102670.68 [0.49, 0.94]0.02ECOG PS 03121.25 [0.23, 6.81]0.803121.08 [0.35, 3.39]0.89 13670.82 [0.61, 1.10]0.193670.85 [0.65, 1.11]0.22Smoking status Current/former6340.76 [0.61, 0.95]0.024810.78 [0.62, 0.99]0.04 Never---490.62 [0.28, 1.40]0.25Stage I-II670.92 [0.40, 2.11]0.84670.71 [0.35, 1.43]0.34 III4630.71 [0.55, 0.91]0.0084630.77 [0.61, 0.98]0.03Time from end of concurrent CRT to randomization < 14 days640.47 [0.24, 0.92]0.03640.45 [0.24, 0.84]0.01 14–28 days1590.59 [0.38, 0.91]0.021590.89 [0.59, 1.34]0.58 >28 days3070.90 [0.64, 1.27]0.553070.79 [0.58, 1.07]0.13Receipt of prophylactic cranial irradiation Yes4380.82 [0.61, 1.09]0.164380.82 [0.63, 1.06]0.13 No2450.71 [0.51, 0.99]0.043300.80 [0.61, 1.05]0.11Best response to concurrent CRT Complete response850.98 [0.49, 1.97]0.96850.96 [0.52, 1.76]0.90 Partial response5160.80 [0.62, 1.02]0.075160.86 [0.68, 1.08]0.19 Stable disease740.54 [0.25, 1.15]0.11740.50 [0.26, 0.95]0.03Radiotherapy schedule Once daily4790.99 [0.49, 2.02]0.985640.84 [0.68, 1.05]0.12 Twice daily2040.59 [0.38, 0.91]0.022040.69 [0.47, 1.02]0.06PD-1/PD-L1 inhibitors type Nivolumab1530.94 [0.59, 1.50]0.791531.01 [0.65, 1.56]0.96 Toripalimab640.89 [0.54, 1.48]0.65640.47 [0.22, 1.01]0.05 Atezolizumab1700.88 [0.58, 1.33]0.541700.88 [0.60, 1.29]0.51 Durvalumab5300.73 [0.57, 0.93]0.015300.76 [0.61, 0.95]0.02 Tislelizumab---850.80 [0.45, 1.43]0.45Platinum type Cisplatin4150.84 [0.65, 1.08]0.174150.80 [0.62, 1.04]0.10 Carboplatin1790.56 [0.35, 0.89]0.011790.61 [0.41, 0.90]0.01ICI administration timing cICRT---850.80 [0.45, 1.43]0.45 sICRT9170.80 [0.67, 0.96]0.029170.78 [0.65, 0.94]0.01Abbreviations: CRT Chemoradiotherapy, CI Confidence interval, cICRT Concurrent immune checkpoint inhibitor plus chemoradiotherapy followed by maintenance immune checkpoint inhibitor, ECOG PS Eastern Cooperative Oncology Group Performance Status, HR Hazard ratio, ICRT Immunotherapy plus chemoradiotherapy, OS Overall survival, P Probability, PD-1 Programmed death-1, PD-L1 Programmed death-ligand 1, PFS Progression-free survival, sICRT Sequential immune checkpoint inhibitor following chemoradiotherapy Subgroup analysis of overall survival and progression-free survival Abbreviations: CRT Chemoradiotherapy, CI Confidence interval, cICRT Concurrent immune checkpoint inhibitor plus chemoradiotherapy followed by maintenance immune checkpoint inhibitor, ECOG PS Eastern Cooperative Oncology Group Performance Status, HR Hazard ratio, ICRT Immunotherapy plus chemoradiotherapy, OS Overall survival, P Probability, PD-1 Programmed death-1, PD-L1 Programmed death-ligand 1, PFS Progression-free survival, sICRT Sequential immune checkpoint inhibitor following chemoradiotherapy Responses Both groups showed comparable results for ORR (RR: 1.00 [0.89, 1.13], P = 0.99), DCR (RR: 1.10 [0.96, 1.25], P = 0.16), complete response (CR) (RR: 1.14 [0.55, 2.34], P = 0.72), partial response (PR) (RR: 0.97 [0.79, 1.21], P = 0.81), stable disease (SD) (RR: 1.24 [1.00, 1.55], P = 0.05) and progressive disease (PD) (RR: 0.76 [0.50, 1.17], P = 0.22) (Table 3, Figure S4). Table 3Tumor responsesResponsesICRTCRTRisk ratio [95% CI] P Event/total%Event/total%ORR197/46942.00%197/46942.00%1.00 [0.89, 1.13]0.99DCR201/34258.77%182/34153.37%1.10 [0.96, 1.25]0.16CR15/3843.91%13/3843.39%1.14 [0.55, 2.34]0.72PR101/38426.30%104/38427.08%0.97 [0.79, 1.21]0.81SD122/34235.67%98/34128.74%1.24 [1.00, 1.55]0.05PD33/3429.65%43/34112.61%0.76 [0.50, 1.17]0.22Abbreviations: CR Complete response, CRT Chemoradiotherapy, CI Confidence interva, DCR Disease control rate, ICRT Immunotherapy plus chemoradiotherapy, ORR Objective response rate, P Probability, PD Progressive disease, PR Partial response, RR Risk ratio, SD Stable disease Table 3Tumor responsesResponsesICRTCRTRisk ratio [95% CI] P Event/total%Event/total%ORR197/46942.00%197/46942.00%1.00 [0.89, 1.13]0.99DCR201/34258.77%182/34153.37%1.10 [0.96, 1.25]0.16CR15/3843.91%13/3843.39%1.14 [0.55, 2.34]0.72PR101/38426.30%104/38427.08%0.97 [0.79, 1.21]0.81SD122/34235.67%98/34128.74%1.24 [1.00, 1.55]0.05PD33/3429.65%43/34112.61%0.76 [0.50, 1.17]0.22Abbreviations: CR Complete response, CRT Chemoradiotherapy, CI Confidence interva, DCR Disease control rate, ICRT Immunotherapy plus chemoradiotherapy, ORR Objective response rate, P Probability, PD Progressive disease, PR Partial response, RR Risk ratio, SD Stable disease Tumor responses Abbreviations: CR Complete response, CRT Chemoradiotherapy, CI Confidence interva, DCR Disease control rate, ICRT Immunotherapy plus chemoradiotherapy, ORR Objective response rate, P Probability, PD Progressive disease, PR Partial response, RR Risk ratio, SD Stable disease Safety Patients treated with ICRT experienced increased rates of TRAEs, TRAEs leading to discontinuation, total irAEs, and grade 3–5 irAEs. The two groups were similar in the comparison of total/grade 3–5/serious TEAEs, and total/grade 3–5 TRAEs (Table 4, Figure S5). Table 4Summary of adverse eventsAdverse eventsICRTCRTRisk ratio [95% CI] P Event/total%Event/total%TEAEs Total TEAEs366/38495.31%342/38489.06%1.06 [0.98, 1.15]0.16 Grade 3–5 TEAEs141/42733.02%100/42623.47%1.58 [0.90, 2.79]0.11 Serious TEAEs78/26429.55%64/26624.06%1.23 [0.92, 1.63]0.16 TEAEs leading to discontinuation43/26416.29%28/26610.53%1.55 [0.99, 2.41]0.05 TEAEs leading to death11/3902.82%6/3911.53%1.82 [0.68, 4.89]0.23TRAEs Total TRAEs293/3840.763021131/38434.11%2.03 [0.40, 10.32]0.39 Grade 3–5 TRAEs172/32353.25%53/32616.26%2.21 [0.45, 10.91]0.33 Serious TRAEs32/26412.12%17/2666.39%1.90 [1.08, 3.33]0.03 TRAEs leading to discontinuation39/30612.75%17/3095.50%2.32 [1.34, 4.01]0.003 TRAEs leading to death6/4391.37%1/4440.23%3.53 [0.74, 16.92]0.11irAEs Total irAEs84/26431.82%27/26610.15%3.13 [2.10, 4.67]< 0.00001 Grade 3–5 irAEs14/2640.053034/2661.50%3.53 [1.18, 10.57]0.02Abbreviations: AE Adverse event, CRT Chemoradiotherapy, CI Confidence interval, ICRT Immunotherapy plus chemoradiotherapy, irAE Immune-related adverse event,P Probability, RR Risk ratio, TEAE Treatment-emergent adverse event, TRAE Treatment-related adverse event Table 4Summary of adverse eventsAdverse eventsICRTCRTRisk ratio [95% CI] P Event/total%Event/total%TEAEs Total TEAEs366/38495.31%342/38489.06%1.06 [0.98, 1.15]0.16 Grade 3–5 TEAEs141/42733.02%100/42623.47%1.58 [0.90, 2.79]0.11 Serious TEAEs78/26429.55%64/26624.06%1.23 [0.92, 1.63]0.16 TEAEs leading to discontinuation43/26416.29%28/26610.53%1.55 [0.99, 2.41]0.05 TEAEs leading to death11/3902.82%6/3911.53%1.82 [0.68, 4.89]0.23TRAEs Total TRAEs293/3840.763021131/38434.11%2.03 [0.40, 10.32]0.39 Grade 3–5 TRAEs172/32353.25%53/32616.26%2.21 [0.45, 10.91]0.33 Serious TRAEs32/26412.12%17/2666.39%1.90 [1.08, 3.33]0.03 TRAEs leading to discontinuation39/30612.75%17/3095.50%2.32 [1.34, 4.01]0.003 TRAEs leading to death6/4391.37%1/4440.23%3.53 [0.74, 16.92]0.11irAEs Total irAEs84/26431.82%27/26610.15%3.13 [2.10, 4.67]< 0.00001 Grade 3–5 irAEs14/2640.053034/2661.50%3.53 [1.18, 10.57]0.02Abbreviations: AE Adverse event, CRT Chemoradiotherapy, CI Confidence interval, ICRT Immunotherapy plus chemoradiotherapy, irAE Immune-related adverse event,P Probability, RR Risk ratio, TEAE Treatment-emergent adverse event, TRAE Treatment-related adverse event Summary of adverse events Abbreviations: AE Adverse event, CRT Chemoradiotherapy, CI Confidence interval, ICRT Immunotherapy plus chemoradiotherapy, irAE Immune-related adverse event,P Probability, RR Risk ratio, TEAE Treatment-emergent adverse event, TRAE Treatment-related adverse event Regarding TEAEs, patients in the ICRT arm had higher incidence of any-grade anorexia, vomiting, hypothyroidism, and hyperthyroidism (Table S5). Additionally, grade 3–5 diarrhea was more frequent in this group (Table S6). With respect to irAEs, patients in the ICRT arm had higher incidence of any-grade pneumonitis, and hypothyroidism (Table S7). However, grade 3–5 irAEs occurred at comparable frequencies in both groups (Table S8). Sensitivity analysis Sensitivity analyses confirmed the consistency of pooled effect estimates for both OS and PFS. No single trial notably affected the heterogeneity or altered the overall results, indicating strong reliability across all included studies (Figure S6). Publication bias As shown in Fig. 5, the funnel plots for survival, PFS, response outcomes, and AEs all appeared relatively symmetrical, suggesting a minimal risk of publication bias. Fig. 5Funnel plots of survival (A), PFSR (B), responses (C), and AEs summary (D) Funnel plots of survival (A), PFSR (B), responses (C), and AEs summary (D) Discussion LS-SCLC continues to pose a formidable therapeutic challenge due to its aggressive clinical course and high relapse rates, even after standard concurrent CRT. Although CRT achieves high initial response rates, long-term survival remains disappointing, and the need for novel, synergistic therapeutic strategies is pressing [19]. In recent years, the success of immunotherapy in extensive-stage SCLC and NSCLC has ignited interest in incorporating immunotherapy into the treatment of LS-SCLC [20, 21]. However, clinicians face considerable uncertainty regarding the true clinical benefit and safety of ICRT, as evidence has thus far been derived from limited and heterogeneous trials with varying designs, follow-up durations, and endpoints [9, 10]. Against this backdrop, our meta-analysis provides an updated synthesis of RCTs that compare ICRT versus CRT alone in LS-SCLC, delivering comprehensive insight into survival outcomes, response rates, and adverse events. Our meta-analysis found that ICRT therapy improved OS and PFS. However, the ICRT therapy was associated with higher rate of irAEs. The observed improvement in OS and PFS with ICRT suggests a potential clinical benefit in LS-SCLC, although the evidence remains preliminary and based on a limited number of trials. Historically, LS-SCLC has been treated with concurrent chemoradiotherapy as the standard of care, achieving 5-year OS rates around 25%, but long-term disease control remains elusive due to rapid relapse and distant metastases [22]. Our pooled analysis reveals a hazard ratio (HR) of 0.80 for OS and 0.78 for PFS in favor of ICRT. This benefit is particularly meaningful in a disease that typically follows an aggressive course and has limited post-progression treatment options. The survival advantage observed may stem from several biological and clinical factors. First, chemoradiotherapy can induce immunogenic cell death, and increase antigen presentation, thereby priming the tumor microenvironment for immune checkpoint blockade [23]. Radiotherapy has also been shown to promote the release of tumor-associated antigens and enhance cross-priming of T cells, especially when administered in a fractionated regimen [24]. These synergistic interactions may enhance the efficacy of immunotherapy when administered shortly after CRT, as reflected by our subgroup analysis showing a greater survival benefit when immunotherapy was initiated within 14 days of CRT completion. This observation is consistent with the hypothesis that timely ICI initiation may capitalize on the transient window of immune stimulation created by CRT, although this requires validation in future dedicated studies. Furthermore, the observed survival benefit despite non-significant differences in ORR suggests that immunotherapy may not necessarily enhance cytotoxic efficacy but may instead improve immune surveillance and long-term disease control. This concept of “disease stabilization” as a survival mechanism has been previously reported in NSCLC and melanoma immunotherapy trials [25]. The progressive separation of survival curves suggests a durable benefit from ICRT, likely driven by sustained immune memory and control of micrometastatic disease, supporting its potential as a promising treatment option pending confirmation in phase 3 and real-world studies [26, 27]. Beyond the overall pooled survival improvement, several subgroup findings provide further insight into factors influencing treatment efficacy. The strongest benefit was observed when ICIs were initiated within 14 days after CRT completion, suggesting that early introduction of immunotherapy may exploit a transient window of immune activation and antigen release triggered by radiotherapy. This finding aligns with preclinical data indicating that immunotherapy enhances T-cell priming and tumor clearance. In addition, patients treated with carboplatin-based chemotherapy derived greater benefit than those receiving cisplatin, potentially due to reduced hematologic toxicity and improved treatment compliance, which allow more effective integration with immunotherapy. Similarly, twice-daily radiotherapy appeared to yield more favorable outcomes than once-daily schedules, possibly through enhanced local control and stronger immune stimulation. Interestingly, patients who did not receive prophylactic cranial irradiation (PCI) also exhibited a trend toward improved OS, which may reflect differences in baseline characteristics or an indirect immune-mediated protective effect. This aligns with a shift in clinical practice: instead of universal PCI, many centers now prefer active MRI surveillance, especially for patients with good responses and expected long-term survival, to reduce neurocognitive risks. Recent multicenter cohort studies and expert reviews suggest that while PCI lowers the incidence of brain metastases, it may not significantly improve overall survival in the MRI era [28, 29]. These findings indicate that, particularly in the immunotherapy era, a selective PCI strategy may better balance survival benefit against neurotoxicity. Together, these subgroup observations underscore that treatment timing, chemotherapy backbone, and radiotherapy parameters may all modulate the synergistic efficacy of ICRT in LS-SCLC and should be prospectively validated in future studies. Nevertheless, identifying reliable predictive biomarkers remains imperative to optimize patient selection for sustained therapeutic efficacy. Additionally, real-world validation is needed to ensure these survival gains translate outside of clinical trial settings, especially in older patients or those with comorbidities. Despite the improvement in survival outcomes, our analysis found no significant difference in conventional tumor response metrics—including ORR, CR, PR, or DCR—between ICRT and CRT, consistent across most trials. This highlights a key distinction between the cytolytic effects of chemotherapy/radiotherapy and the immune-mediated mechanisms of ICIs, which often yield delayed or unconventional responses [27]. The absence of a response advantage suggests that immunotherapy primarily enhances durable disease control rather than initial tumor shrinkage. Indeed, we observed a trend toward higher SD and lower PD rates in the ICRT group, indicating stabilization rather than regression. As RECIST-based assessments were often performed soon after CRT—explicitly reported only in ADRIATIC and STIMULI [9, 10]—they may capture acute cytotoxic effects while underestimating the delayed benefits of immune activation. This explains why survival gains can occur without parallel improvement in radiographic response, a pattern also observed in other ICI-treated malignancies such as renal cell carcinoma and melanoma [9, 10, 27]. Furthermore, RECIST v1.1 has intrinsic limitations in immunotherapy, as it cannot account for pseudo-progression or other immune-related phenomena [30, 31]. The lack of iRECIST-based evaluation in most trials may therefore underestimate true immunologic benefit. Moreover, RECIST does not capture biological alterations such as necrosis, immune infiltration, or metabolic changes, which could better represent treatment efficacy [32]. Future studies incorporating functional imaging, ctDNA dynamics, or immune profiling [33] are warranted to more accurately evaluate immunotherapy responses. Overall, survival endpoints appear to better reflect the clinical benefit of ICRT than conventional response criteria in LS-SCLC. Safety remains a critical concern in the implementation of immunotherapy in LS-SCLC, especially given the already significant toxicity burden associated with concurrent CRT. Our meta-analysis revealed that while the addition of ICIs significantly increased the incidence of irAEs compared to CRT alone. The most frequently observed irAEs, hypothyroidism and pneumonitis, are consistent with known irAEs of PD-1/PD-L1 inhibitors. Hypothyroidism is generally manageable with hormone replacement and rarely leads to treatment discontinuation [34]. However, pneumonitis is more concerning, particularly in the context of thoracic radiotherapy, which independently increases the risk of radiation-induced lung injury [34]. Differentiating between immune-related pneumonitis and radiation pneumonitis is clinically challenging, and mismanagement can lead to serious outcomes. Close radiographic monitoring and early corticosteroid intervention are essential [35]. The incidence of grade 3–5 pneumonitis in ICRT-treated patients in our analysis, while low, underscores the need for caution in patients with baseline pulmonary comorbidities [36]. Interestingly, the rates of hematologic and gastrointestinal toxicities did not differ significantly between groups, suggesting that the immune-related toxicities were additive but not synergistic with chemotherapy-induced or radiation-induced side effects. This finding may be partially explained by the better tolerability of carboplatin-based regimens, which were more frequently used in the ICRT arms. Moreover, PD-L1 inhibitors (e.g., durvalumab, atezolizumab), which were commonly used in the included studies, are associated with lower rates of irAEs compared to PD-1 inhibitors, potentially contributing to the manageable toxicity profile observed [37]. Despite these findings, the importance of patient selection and toxicity monitoring cannot be overstated. Pre-existing autoimmune disease, prior thoracic radiation, and poor pulmonary reserve are relative contraindications that must be carefully evaluated. The development of predictive markers for irAE risk—such as HLA typing, cytokine profiles, or autoantibody signatures—could further optimize safety [38]. Additionally, treatment sequencing and scheduling may play a role in minimizing overlapping toxicities: for example, staggering immunotherapy initiation to 7–14 days post-CRT may allow partial resolution of radiation-induced inflammation before initiating immune activation [39]. Thoracic radiotherapy induces vascular and immune activation that can overlap with ICI-mediated inflammation, potentially increasing the risk of pneumonitis or esophagitis. Post-CRT PD-L1 consolidation generally demonstrates acceptable pneumonitis rates, whereas concurrent ICI exposure may heighten risk, though evidence remains inconsistent [40]. Because AE data were rarely stratified by treatment sequence, a formal comparison between concurrent and sequential ICRT was not feasible. These findings highlight the importance of cautious patient selection and standardized, sequence-specific AE reporting in future LS-SCLC trials. In summary, while ICRT is associated with a higher risk of irAEs, these events are largely predictable, manageable, and do not appear to significantly compromise treatment completion or efficacy. With proper monitoring protocols, multidisciplinary care, and timely intervention, the toxicity profile of ICRT is acceptable and does not outweigh its survival benefits. Despite the strengths of our analysis, several limitations warrant discussion. First, the number of included RCTs (n = 6) and the total sample size (n = 1036) remain relatively modest, limiting the power of subgroup analyses and increasing susceptibility to study-level biases. Second, four of the six trials were available only as abstracts from ASCO or AACR, which limited access to full datasets and raised concerns about publication and reporting bias. While funnel plot analyses showed acceptable symmetry, the inclusion of unpublished or interim results may introduce instability in effect estimates. Third, heterogeneity in trial design—such as differences in timing of immunotherapy, radiotherapy regimens, PD-1/PD-L1 inhibitors used, patient inclusion/exclusion criteria, and follow-up time—could confound pooled estimates. Although we used random-effects models where appropriate and confirmed result robustness in sensitivity analyses, unmeasured variables may still influence outcomes. Fourth, the included trials differed in the sequence of immunotherapy relative to CRT, which may introduce heterogeneity and bias into pooled estimates. Fifth, response evaluation was not uniformly reported across studies, with only some specifying RECIST v1.1 and few providing details on assessment timing. This lack of consistency may have introduced heterogeneity into the pooled response outcomes. Finally, most studies lacked biomarker-driven subgroup data, precluding analysis of predictive factors such as PD-L1 expression. As the field evolves, future trials should prioritize translational endpoints and real-world validation to guide precision immunotherapy in LS-SCLC. Conclusion The addition of immunotherapy to standard concurrent CRT appears to be associated with improved OS and PFS in patients with LS-SCLC. The observed benefits appear durable and consistent across most subgroups. Despite an increased risk of irAEs, the overall safety profile remains acceptable. These findings suggest that ICRT may be a promising investigational first-line approach in LS-SCLC and highlight the need for further prospective studies to confirm its efficacy and safety. Supplementary Information Supplementary Material 1. Figure S1 Cochrane Risk Assessment. Supplementary Material 1. Figure S1 Cochrane Risk Assessment. Supplementary Material 2. Figure S2 Forest plots of OSR at 6-60 months associated with ICRT versus CRT. Supplementary Material 2. Figure S2 Forest plots of OSR at 6-60 months associated with ICRT versus CRT. Supplementary Material 3. Figure S3 Forest plots of PFSR at 6-48 months associated with ICRT versus CRT. Supplementary Material 3. Figure S3 Forest plots of PFSR at 6-48 months associated with ICRT versus CRT. Supplementary Material 4. Figure S4 Forest plots of responses associated with ICRT versus CRT. Supplementary Material 4. Figure S4 Forest plots of responses associated with ICRT versus CRT. Supplementary Material 5. Figure S5 Forest plots of safety summary associated with ICRT versus CRT. Supplementary Material 5. Figure S5 Forest plots of safety summary associated with ICRT versus CRT. Supplementary Material 6. Figure S6 Sensitivity analysis of overall survival (A), and progression-free survival (B). Supplementary Material 6. Figure S6 Sensitivity analysis of overall survival (A), and progression-free survival (B). Supplementary Material 7. Table S1 Search strategy. Supplementary Material 7. Table S1 Search strategy. Supplementary Material 8. Table S2 Methodological quality assessments (Jadad scale) of the included studies. Supplementary Material 8. Table S2 Methodological quality assessments (Jadad scale) of the included studies. Supplementary Material 9. Table S3 GRADE quality assessment by therapeutic strategy and study design for the outcomes. Supplementary Material 9. Table S3 GRADE quality assessment by therapeutic strategy and study design for the outcomes. Supplementary Material 10. Table S4 Inclusion/Exclusion criteria of the included studies. Supplementary Material 10. Table S4 Inclusion/Exclusion criteria of the included studies. Supplementary Material 11. Table S5 Any grade treatment-emergent adverse events. Supplementary Material 11. Table S5 Any grade treatment-emergent adverse events. Supplementary Material 12. Table S6 Grade 3-5 treatment-emergent adverse events. Supplementary Material 12. Table S6 Grade 3-5 treatment-emergent adverse events. Supplementary Material 13. Table S7 Any grade immune-related adverse events. Supplementary Material 13. Table S7 Any grade immune-related adverse events. Supplementary Material 14. Table S8 Grade 3-5 immune-related adverse events. Supplementary Material 14. Table S8 Grade 3-5 immune-related adverse events.